+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Artificial Pancreas Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

  • PDF Icon

    Report

  • 139 Pages
  • December 2022
  • Region: Global
  • GlobalData
  • ID: 5714515
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's Medical Devices sector report, “Artificial Pancreas Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update' provides comprehensive information about the Artificial Pancreas pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Artificial Pancreas helps people with diabetes, primarily type 1, automatically and continuously control their blood glucose level by providing the substitute endocrine functionality of a healthy pancreas.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Artificial Pancreas under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Artificial Pancreas and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

The report enables you to:
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Artificial Pancreas under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Artificial Pancreas Overview

3 Products under Development
3.1 Artificial Pancreas - Pipeline Products by Stage of Development
3.2 Artificial Pancreas - Pipeline Products by Territory
3.3 Artificial Pancreas - Pipeline Products by Regulatory Path
3.4 Artificial Pancreas - Pipeline Products by Estimated Approval Date
3.5 Artificial Pancreas - Ongoing Clinical Trials

4 Artificial Pancreas - Pipeline Products under Development by Companies
4.1 Artificial Pancreas Companies - Pipeline Products by Stage of Development
4.2 Artificial Pancreas - Pipeline Products by Stage of Development

5 Artificial Pancreas Companies and Product Overview
5.1 Admetsys Corp Company Overview
5.2 Advanced Biosensors-Ohio LLC Company Overview
5.3 AiTA Bio Inc Company Overview
5.4 Beta Bionics Inc Company Overview
5.5 Beta-O2 Technologies Ltd Company Overview
5.6 Bigfoot Biomedical Inc Company Overview
5.7 BioTex Inc Company Overview
5.8 Captix Biomedical Pty Ltd Company Overview
5.9 Cerco Medical LLC Company Overview
5.10 Children's Hospital of Philadelphia Company Overview
5.11 Converge Biotech, Inc. Company Overview
5.12 Covalor Medical, LLC Company Overview
5.13 De Montfort University Company Overview
5.14 Debiotech SA Company Overview
5.15 Defymed SAS Company Overview
5.16 Diabeloop SA Company Overview
5.17 EOFlow Co Ltd Company Overview
5.18 Giner Inc Company Overview
5.19 Harvard John A Paulson School of Engineering and Applied Sciences Company Overview
5.20 Healios Inc Company Overview
5.21 Humacyte Inc Company Overview
5.22 Imperial College London Company Overview
5.23 Indian Institute of Science Company Overview
5.24 Inreda Diabetic BV Company Overview
5.25 Joslin Diabetes Center Company Overview
5.26 Kailian Medical Technology Co Ltd Company Overview
5.27 Kencak LLC Company Overview
5.28 McGill University Company Overview
5.29 Medtronic Inc Company Overview
5.30 Medtronic MiniMed Inc Company Overview
5.31 MicroTech Medical Co Ltd Company Overview
5.32 Miromatrix Medical Inc Company Overview
5.33 Modular Medical Inc Company Overview
5.34 Pacific Diabetes Technologies Inc Company Overview
5.35 Pancreum, LLC Company Overview
5.36 PharmaCyte Biotech Inc Company Overview
5.37 Polytechnic University of Valencia Company Overview
5.38 Rensselaer Polytechnic Institute Company Overview
5.39 Senseonics Holdings Inc Company Overview
5.40 Shenzhen Huayuan Regenerative Medicine Co Ltd Company Overview
5.41 Stanford University Company Overview
5.42 Tandem Diabetes Care Inc Company Overview
5.43 TecMed Inc Company Overview
5.44 TypeZero Technologies LLC Company Overview
5.45 U-Needle BV Company Overview
5.46 Universidad Autonoma de Madrid Company Overview
5.47 University of California San Francisco Company Overview
5.48 University of California Santa Barbara Company Overview
5.49 University of Cambridge Company Overview
5.50 University of Florida Company Overview
5.51 University of Minnesota Company Overview
5.52 University of Newcastle Company Overview
5.53 University of Queensland Company Overview
5.54 WaveForm Technologies Inc Company Overview
5.55 Xeris Biopharma Holdings Inc Company Overview
5.56 Yale University Company Overview
5.57 Ypsomed Holding AG Company Overview

6 Artificial Pancreas - Recent Developments
6.1 Nov 23, 2022: Medtronic Reports Quarterly Earnings
6.2 Nov 22, 2022: Medtronic reports second quarter fiscal 2023 financial results
6.3 Nov 15, 2022: Medtronic Set to Announce Earnings on Tuesday
6.4 Sep 26, 2022: Miromatrix CEO Jeff Ross to Present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event
6.5 Sep 22, 2022: Insulet to Announce Third Quarter 2022 Financial Results on November 3, 2022
6.6 Sep 20, 2022: Miromatrix CEO Jeff Ross to Present at the Bioregate European Regenerative Medicine Forum
6.7 Sep 07, 2022: Medtronic to appear at September investor conferences
6.8 Aug 23, 2022: Medtronic reports first quarter fiscal 2023 financial results
6.9 Aug 23, 2022: Medtronic Announces Quarterly Earnings Results
6.10 Aug 15, 2022: Miromatrix Reports Second Quarter 2022 Results and Provides Corporate Update
6.11 Aug 10, 2022: Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events
6.12 Aug 03, 2022: Xeris Biopharma to Report Second Quarter 2022 Financial Results on August 10, 2022
6.13 Aug 01, 2022: Miromatrix to Report Second Quarter 2022 Financial Results
6.14 Jul 11, 2022: PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
6.15 Jun 27, 2022: Medtronic Board appoints Lidia Fonseca as a new director
6.16 Jun 02, 2022: Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference
6.17 May 27, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results
6.18 May 26, 2022: Bigfoot Biomedical Strengthens Leadership Team with Experienced Chief Commercial Officer
6.19 May 26, 2022: Medtronic reports full year and fourth quarter fiscal year 2022 financial results announces 8% dividend increase
6.20 May 25, 2022: Miromatrix Announces Participation in the 19th Annual Craig-Hallum Institutional Investor Conference
6.21 May 11, 2022: Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events
6.22 May 05, 2022: Insulet Announces CEO Transition
6.23 May 05, 2022: Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year
6.24 May 04, 2022: Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022
6.25 Apr 19, 2022: Miromatrix CEO Jeff Ross to Present at the 2022 Cell & Gene Meeting on the Med
6.26 Apr 07, 2022: Insulet to Announce First Quarter 2022 Financial Results on May 5, 2022
6.27 Mar 29, 2022: Miromatrix Moves into New Headquarters Complete with In-House Manufacturing Capabilities
6.28 Mar 17, 2022: Miromatrix to Report Fourth Quarter and Full Year 2021 Financial Results
6.29 Mar 10, 2022: Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events
6.30 Mar 04, 2022: Xeris Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
6.31 Mar 01, 2022: Miromatrix Names Jim Douglas as New Chief Financial Officer
6.32 Feb 22, 2022: PharmaCyte Biotech announces genetic stability of cytochrome P450 gene and site of integration
6.33 Feb 16, 2022: Insulet to Present at Upcoming Investor Conferences
6.34 Feb 14, 2022: PharmaCyte Biotech updates status of investigational new drug application to FDA
6.35 Feb 07, 2022: Insulet Announces Board Appointment of Elizabeth Weatherman and Retirement of David Lemoine
6.36 Jan 12, 2022: Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2021
6.37 Jan 04, 2022: Medtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference
6.38 Jan 04, 2022: PharmaCyte Biotech study proves capsule material is not toxic for encapsulated cells

7 Appendix
7.1 Methodology
7.2 About the Publisher
7.3 Contact the Publisher
7.4 Disclaimer

List of Tables
  • Artificial Pancreas - Pipeline Products by Stage of Development
  • Artificial Pancreas - Pipeline Products by Segment
  • Artificial Pancreas - Pipeline Products by Territory
  • Artificial Pancreas - Pipeline Products by Regulatory Path
  • Artificial Pancreas - Pipeline Products by Estimated Approval Date
  • Artificial Pancreas - Ongoing Clinical Trials
  • Artificial Pancreas Companies - Pipeline Products by Stage of Development
  • Artificial Pancreas - Pipeline Products by Stage of Development
  • Glossary
List of Figures
  • Artificial Pancreas - Pipeline Products by Stage of Development
  • Artificial Pancreas - Pipeline Products by Territory
  • Artificial Pancreas - Pipeline Products by Regulatory Path
  • Artificial Pancreas - Pipeline Products by Estimated Approval Date
  • Artificial Pancreas - Ongoing Clinical Trials

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Admetsys Corp
  • Advanced Biosensors-Ohio LLC
  • AiTA Bio Inc
  • Beta Bionics Inc
  • Beta-O2 Technologies Ltd
  • Bigfoot Biomedical Inc
  • BioTex Inc
  • Captix Biomedical Pty Ltd
  • Cerco Medical LLC
  • Children's Hospital of Philadelphia
  • Converge Biotech, Inc.
  • Covalor Medical, LLC
  • De Montfort University
  • Debiotech SA
  • Defymed SAS
  • Diabeloop SA
  • EOFlow Co Ltd
  • Giner Inc
  • Harvard John A Paulson School of Engineering and Applied Sciences
  • Healios Inc
  • Humacyte Inc
  • Imperial College London
  • Indian Institute of Science
  • Inreda Diabetic BV
  • Joslin Diabetes Center
  • Kailian Medical Technology Co Ltd
  • Kencak LLC
  • McGill University
  • Medtronic Inc
  • Medtronic MiniMed Inc
  • MicroTech Medical Co Ltd
  • Miromatrix Medical Inc
  • Modular Medical Inc
  • Pacific Diabetes Technologies Inc
  • Pancreum, LLC
  • PharmaCyte Biotech Inc
  • Polytechnic University of Valencia
  • Rensselaer Polytechnic Institute
  • Senseonics Holdings Inc
  • Shenzhen Huayuan Regenerative Medicine Co Ltd
  • Stanford University
  • Tandem Diabetes Care Inc
  • TecMed Inc
  • TypeZero Technologies LLC
  • U-Needle BV
  • Universidad Autonoma de Madrid
  • University of California San Francisco
  • University of California Santa Barbara
  • University of Cambridge
  • University of Florida
  • University of Minnesota
  • University of Newcastle
  • University of Queensland
  • WaveForm Technologies Inc
  • Xeris Biopharma Holdings Inc
  • Yale University
  • Ypsomed Holding AG